Informed carcinogenicity assessments using LCDB Plus
Perform robust carcinogenicity assessments using advanced Lhasa TD₅₀ values. Unlock regulatory-approved TD₅₀ methodology and defensible reliability scoring in the new Lhasa Carcinogenic Potency Database (LCDB) Plus.
Streamline the time and resources required for ICH M7 classification of Class 1 impurities and other carcinogenicity assessments.
Discover simple identification of relevant study data, including a clear indication of the most sensitive site within the most robust study, contextualised reliability scores, a TD₅₀ calculator for proprietary datasets, and more!
From legacy Gold TD₅₀ values to robust Lhasa-derived TD₅₀ methodology, and now, LCDB Plus’ innovative functionality, which applies Lhasa’s bespoke TD₅₀ methodology to your datasets:
Access Robust Carcinogenicity Potency Data
An expert carcinogenicity database is crucial in demonstrating robust assessment. With LCDB Plus, we provide access to 127% more carcinogenicity data, which facilitates informed decision-making using defensible and reproducible TD₅₀ values for both new and proprietary compounds.
Ensure confident compliance of proprietary compounds
Perform reliable TD₅₀ calculations on your own carcinogenicity data using a transparent, regulatory-approved TD₅₀ methodology from Lhasa Limited.
Facilitate informed decision-making using quality data
Trust an expansive, curated and peer-reviewed dataset alongside Lhasa-derived TD₅₀ values for long-term carcinogenicity study data
Demonstrate robust assessment with relevance and reliability
Judge the relevance of data easily using Lhasa Reliability Scoring, efficient for ICH M7 Class 1 impurities, and pinpointing those studies suitable for dose-response modelling.
LCDB Plus ignites intelligent carcinogenicity data searching
The extended dataset, specifically 4,000+ structures within LCDB Plus, is designed to enhance scientific judgment and accelerate expert review.
This is achievable through combined functionalities that prioritise the delivery of the most relevant data:
Quickly view the most sensitive tumour sites, from the most sensitive species, from the most robust study
The advanced features of the database mean you can quickly unlock and assess data quality, whilst also utilising a TD₅₀ methodology that is aligned with regulatory submission.
The carcinogenic database is peer-reviewed by Lhasa Scientists.
Mitigate the need for duplicate analytical testing and deploy LCDB Plus’ expert TD₅₀ values to make informed decisions on pre-existing experimental data that has been expertly validated.
Speak to a Scientist about LCDB Plus:
Leverage regulatory-aligned methodology within a TD₅₀ calculator to gain bespoke TD₅₀ values for your own compound data.
Reduce the time required to search, identify and interpret carcinogenic data for efficient evidence-based ICH M7 classification of Class 1 impurities.
Navigate decision-making on acceptable intake (AI) limits and potential carcinogenic potency with validated and transparent data.
Demonstrate meaningful results and confirm the robustness of your assessments with our reliability scoring and report output functionality.
Schedule an LCDB Plus Introduction:
Speak to a Scientist
Join the Discussion
Robust Carcinogenicity Assessments: Leveraging New and Existing TD50 Data using LCDB Plus | 29th April 2026
Join Lhasa Limited for an insightful exploration of robust carcinogenicity assessments and how to leverage new and existing TD50 data to inform decision-making.
We will be joined by industry expert Susan Felter, Vice President at Procter & Gamble, to outline how an expert review approach solves carcinogenicity data quality challenges.
Visit our events page for the full agenda. Register to secure your place and discover the carcinogenicity database for yourself!
Explore our related solutions that can help you transform the carcinogenic potency dataset into a complete in silico carcinogenicity risk assessment workflow: Derek, Sarah, Vitic and Acrostic.